SCHEMBL7862894

SCHEMBL7862894

CSc1ccc(-c2ccc(/C(CCC(=O)O)=N\O)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 1/20 0.50
HDAC8 Q9BY41 1/20 0.45
MMP12 P39900 1/20 0.43
MMP13 P45452 1/20 0.43
FFAR1 O14842 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 2/20 0.42
CYP1A2 P05177 1/20 0.42
RAB9A P51151 1/20 0.42
HIF1A Q16665 1/20 0.42
MMP2 P08253 2/20 0.42
MMP9 P14780 2/20 0.42
MMP8 P22894 1/20 0.42
PLK1 P53350 1/20 0.40
FFAR4 Q5NUL3 1/20 0.38
KMT2A Q03164 1/20 0.37
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
PPARA Q07869 2/20 0.36
PPARG P37231 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7862896 1.00 HAO1 (0.50) HAO1HDAC8MMP12MMP13FFAR1
SCHEMBL7437233 0.83 RARB (0.40) HAO1MMP12MMP13FFAR1CYP1A2
SCHEMBL7437227 0.83 RARB (0.40) HAO1MMP12MMP13FFAR1CYP1A2
SCHEMBL7764807 0.83 KMT2A (0.56) HDAC8FFAR1SMN1; SMN2LMNACYP1A2
SCHEMBL7764810 0.83 KMT2A (0.56) HDAC8FFAR1SMN1; SMN2LMNACYP1A2
SCHEMBL7862887 0.81 SMN1; SMN2 (0.66) HAO1MMP12MMP13FFAR1SMN1; SMN2
SCHEMBL7436943 0.80 MGLL (0.41) HAO1MMP12MMP13PPARG
SCHEMBL7436938 0.80 MGLL (0.41) HAO1MMP12MMP13PPARG
SCHEMBL10021382 0.80 HDAC8 (0.48) HDAC8FFAR1SMN1; SMN2LMNACYP1A2
SCHEMBL4434852 0.80 ALDH1A1 (0.54) HAO1HDAC8MMP13FFAR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6239288-B1 RHEUMATIC DISEASES WARNER-LAMBERT COMPANY 2001-05-29 US claimed
US-20010000513-A1 Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY 2001-04-26 US claimed
EP-0927156-A1 BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES WARNER-LAMBERT COMPANY (US) 1999-07-07 EP claimed
WO-1998009940-A1 BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES WARNER-LAMBERT COMPANY (US) 1998-03-12 WO claimed
US-6307089-B2 Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY 2001-10-23 US disclosed
US-6239288-B1 RHEUMATIC DISEASES WARNER-LAMBERT COMPANY 2001-05-29 US disclosed
US-20010000513-A1 Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY 2001-04-26 US disclosed
EP-0927156-A1 BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES WARNER-LAMBERT COMPANY (US) 1999-07-07 EP disclosed
WO-1998009940-A1 BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES WARNER-LAMBERT COMPANY (US) 1998-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010000513-A1 Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases MMP26, MMP1, MMP9 HAO1 1275/4885HDAC8 878/4885MMP12 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.